Actuate Therapeutics (NASDAQ:ACTU) Earns Buy Rating from Analysts at B. Riley

B. Riley began coverage on shares of Actuate Therapeutics (NASDAQ:ACTU) in a report issued on Monday morning, MarketBeat Ratings reports. The firm issued a buy rating and a $20.00 price objective on the stock.

A number of other brokerages also recently commented on ACTU. HC Wainwright restated a “buy” rating and set a $20.00 price objective on shares of Actuate Therapeutics in a research note on Monday, August 18th. Wall Street Zen downgraded Actuate Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, August 22nd. Three equities research analysts have rated the stock with a Buy rating, According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $20.33.

Actuate Therapeutics Trading Down 1.7%

Shares of NASDAQ ACTU opened at $8.05 on Monday. Actuate Therapeutics has a twelve month low of $5.47 and a twelve month high of $11.99. The business has a 50 day simple moving average of $7.06 and a 200-day simple moving average of $7.92.

Actuate Therapeutics (NASDAQ:ACTU) last issued its quarterly earnings data on Thursday, August 14th. The company reported ($0.30) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.11).

Insider Transactions at Actuate Therapeutics

In other Actuate Therapeutics news, Director Aaron G.L. Fletcher purchased 71,428 shares of the firm’s stock in a transaction dated Friday, June 27th. The stock was bought at an average price of $7.00 per share, with a total value of $499,996.00. Following the completion of the purchase, the director owned 196,428 shares in the company, valued at $1,374,996. This trade represents a 57.14% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Equity Cof Lp Bios purchased 71,428 shares of the firm’s stock in a transaction dated Friday, June 27th. The stock was acquired at an average cost of $7.00 per share, with a total value of $499,996.00. Following the purchase, the director owned 196,428 shares of the company’s stock, valued at approximately $1,374,996. This represents a 57.14% increase in their position. The disclosure for this purchase can be found here. Over the last quarter, insiders acquired 214,284 shares of company stock valued at $1,499,988. 69.34% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. BIOS Capital Management LP acquired a new stake in shares of Actuate Therapeutics in the fourth quarter valued at $78,753,000. Envestnet Asset Management Inc. acquired a new stake in shares of Actuate Therapeutics in the fourth quarter valued at $83,000. Mercer Global Advisors Inc. ADV acquired a new stake in shares of Actuate Therapeutics in the fourth quarter valued at $130,000. Voss Capital LP lifted its holdings in shares of Actuate Therapeutics by 157.7% in the first quarter. Voss Capital LP now owns 142,381 shares of the company’s stock valued at $964,000 after buying an additional 87,135 shares during the period. Finally, OMERS ADMINISTRATION Corp acquired a new stake in shares of Actuate Therapeutics in the fourth quarter valued at $84,000.

About Actuate Therapeutics

Actuate Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company’s lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer.